• In late February and early March 2026, ACADIA Pharmaceuticals reported higher full-year 2025 earnings, issued 2026 revenue guidance of US$1.22–1.28 billion, received a negative CHMP opinion on trofinetide for Rett syndrome in the EU, and added experienced finance executive Jonathan M. Poole to its Board and Audit Committee.
• The CHMP’s refusal of trofinetide, despite a pivotal trial meeting its key endpoints, raises important questions about ACADIA’s ability to expand Rett syndrome treatment access beyond the U.S. and diversify revenue geographically.
• We’ll now examine how the EU setback for trofinetide could reshape ACADIA’s investment narrative, especially its assumptions about Rett syndrome expansion.

Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

ACADIA Pharmaceuticals Investment Narrative Recap

To own ACADIA, you need to believe in its ability to build a durable CNS and rare-disease franchise around NUPLAZID and DAYBUE while gradually broadening its pipeline. The negative CHMP opinion on trofinetide directly challenges the near term Rett expansion thesis in Europe, while the biggest current risk remains ACADIA’s reliance on a narrow, largely U.S. focused commercial base and the long term exposure of NUPLAZID to pricing and reimbursement pressure.

Against that backdrop, the company’s 2026 revenue guidance of US$1.22–1.28 billion, with NUPLAZID and DAYBUE contributing roughly equally, is particularly important. It frames how much near term growth still depends on U.S. execution in Parkinson’s disease psychosis and Rett syndrome, even as European regulators push back on trofinetide. How actual results compare with this guidance may influence how investors weigh the recent EU setback against ACADIA’s core commercial trajectory.

Yet behind the solid 2026 revenue guide, one risk that investors should be aware of is ACADIA’s continued dependence on a relatively narrow product base and...

ACADIA Pharmaceuticals’ narrative projects $1.4 billion revenue and $306.0 million earnings by 2028.

Uncover how ACADIA Pharmaceuticals' forecasts yield a $31.21 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue of about US$1.3 billion and earnings of only US$57.1 million by 2028, so this fresh EU pushback could reinforce their view of persistent regulatory and pricing headwinds while other investors may still see more room for DAYBUE and NUPLAZID to outperform those gloomy assumptions.

Explore 8 other fair value estimates on ACADIA Pharmaceuticals - why the stock might be worth over 6x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ACADIA Pharmaceuticals research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free ACADIA Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ACADIA Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.